Interleukin-8 mediates resistance to antiangiogenic agent sunitinib in renal cell carcinoma.

Cancer Research
Dan HuangBin Tean Teh

Abstract

The broad spectrum kinase inhibitor sunitinib is a first-line therapy for advanced clear cell renal cell carcinoma (ccRCC), a deadly form of kidney cancer. Unfortunately, most patients develop sunitinib resistance and progressive disease after about 1 year of treatment. In this study, we evaluated the mechanisms of resistance to sunitinib to identify the potential tactics to overcome it. Xenograft models were generated that mimicked clinical resistance to sunitinib. Higher microvessel density was found in sunitinib-resistant tumors, indicating that an escape from antiangiogenesis occurred. Notably, escape coincided with increased secretion of interleukin-8 (IL-8) from tumors into the plasma, and coadministration of an IL-8 neutralizing antibody resensitized tumors to sunitinib treatment. In patients who were refractory to sunitinib treatment, IL-8 expression was elevated in ccRCC tumors, supporting the concept that IL-8 levels might predict clinical response to sunitinib. Our results reveal IL-8 as an important contributor to sunitinib resistance in ccRCC and a candidate therapeutic target to reverse acquired or intrinsic resistance to sunitinib in this malignancy.

References

Dec 11, 1992·Science·A E KochR M Strieter
May 1, 1994·The Journal of Experimental Medicine·D R SmithR M Strieter
Sep 7, 2001·Cytokine & Growth Factor Reviews·K Xie
Apr 16, 2005·Neuro-oncology·Daniel J BratErwin G Van Meir
Dec 26, 2006·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Premal H PatelRobert J Motzer
Jan 12, 2007·The New England Journal of Medicine·Robert J MotzerRobert A Figlin
Mar 9, 2007·Nature·Christopher GreenmanMichael R Stratton
Aug 11, 2007·Nature Reviews. Drug Discovery·Sandrine FaivreEric Raymond
Aug 22, 2007·The Journal of Immunology : Official Journal of the American Association of Immunologists·Wendy W J van de SandeAlex van Belkum
Oct 19, 2007·Proceedings of the National Academy of Sciences of the United States of America·John M L EbosRobert S Kerbel
Jul 4, 2008·Nature Reviews. Cancer·Lee M Ellis, Daniel J Hicklin
Jul 25, 2008·Nature Reviews. Cancer·Gabriele Bergers, Douglas Hanahan
Oct 18, 2008·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Lee M Ellis, Daniel J Hicklin
Nov 5, 2008·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·David J J Waugh, Catherine Wilson
Apr 4, 2009·Cancer Chemotherapy and Pharmacology·David J Reeves, Chin Y Liu

❮ Previous
Next ❯

Citations

Oct 19, 2012·Angiogenesis·Patricia FergelotAndreas Bikfalvi
Sep 27, 2012·Journal of Mammary Gland Biology and Neoplasia·Robert S Kerbel
Mar 22, 2012·Current Oncology Reports·Maria Hernandez-YanezAmado J Zurita
Apr 11, 2013·Drugs·Bernard EscudierGuru Sonpavde
Sep 25, 2012·Nature Reviews. Cancer·Barbara Sennino, Donald M McDonald
Aug 29, 2013·Nature Reviews. Clinical Oncology·Joaquim BellmuntJonathan E Rosenberg
Oct 15, 2010·Annals of Oncology : Official Journal of the European Society for Medical Oncology·T PowlesS Agrawal
Apr 6, 2011·Annals of Oncology : Official Journal of the European Society for Medical Oncology·A J ZuritaJ V Heymach
Aug 8, 2012·The Journal of Pharmacology and Experimental Therapeutics·Qingyu ZhouJames M Gallo
Jul 9, 2011·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Carmine CarboneDavide Melisi
Aug 12, 2010·Molecular Cancer Therapeutics·Rupal S BhattJames W Mier
Apr 26, 2012·Molecular Cancer Therapeutics·Peter B MakhovVladimir M Kolenko
May 29, 2012·Molecular Cancer Research : MCR·Eric JonaschW Kimryn Rathmell
Sep 29, 2012·BMC Medicine·Naveen S VasudevRosamonde E Banks
Aug 11, 2010·Genome Biology·Steven Jm JonesMarco A Marra
Nov 22, 2013·PloS One·Ting ZhangHaifeng Yang
Nov 15, 2012·Pharmacogenomics·Cristina Rodríguez-Antona, Jesús García-Donas
Jul 24, 2014·Future Oncology·Marco BartolottiAlba A Brandes
Jul 31, 2012·Angiogenesis·Jonathan C WeltiAndrew R Reynolds
Nov 26, 2013·Biochimica Et Biophysica Acta·Franziska StehleBarbara Seliger
Sep 22, 2010·Expert Opinion on Therapeutic Targets·Autumn L JacksonWilliam Y Kim
Apr 4, 2015·Expert Review of Molecular Diagnostics·Jason Yongsheng ChanMin-Han Tan
Nov 17, 2015·Expert Review of Anticancer Therapy·Francesco MassariLiang Cheng

❮ Previous
Next ❯

Related Concepts

Related Feeds

Adenocarcinoma, Clear Cell

Clear Cell Adenocarcinoma is a tumor that arises in the female genital tract and is characterized by cells that appear clear under the microscope. Discover the latest research here.

Angiogenesis Inhibitors to Treat Cancer

Cancer treatments including angiogenesis inhibitors prevent tumor cells from receiving nutrients and oxygen. Here is the latest research on angiogenesis inhibitors for the treatment of cancer.